Nadora Healthcare offers a multi-specialty clinical trial location with long-stay overnight capability; We’ve quickly became a desired study site for pain management, musculoskeletal and respiratory trials. Click below to learn more about placing your trial at Nadora Healthcare.
Request information about Nadora Healthcare and our capabilities. Nadora Healthcare will complete a CDA with your organization so we can evaluate your protocol and begin the evaluation process. We'll conduct an introductory phone call and learn more about each other.
Nadora Healthcare will submit a budget proposal following review of your protocol & study synopsis. We will schedule a site visit for your organization (and sponsor if required) and all parties will approve the initiation of the trial at our location.
Nadora Healthcare will begin to work with our recruitment team to meet recruitment milestones of qualified participants. We have ready access to all population groups and are able to recruit populations from 10 to 300 participants per trial.
Nadora Healthcare will compile clinical trial data pursuant to the trial protocol for accurate reporting to your organization and sponsor. Our research associates adhere to the ICH-GCP standards to produce our reports and we can provide a full clinical study report if requested.
Plantar fibromatosis (PFI) is a rare disease of the foot. In PFI, one or more slow-growing, benign (non-cancerous) lumps form along the bottom of the foot. The lump(s) enlarge and become swollen. Walking and even bearing weight on the affected foot can be painful.
Plantar fibromatosis (also known as Ledderhose disease) is a rare pathology of the plantar aponeurosis characterized by disordered fibrous tissue and the subsequent formation of nodules. The primary symptoms include one or more slow-growing benign lumps that form along the medial longitudinal arch which usually become painful and swollen. The condition may reduce quality of life and can cause functional disability, leading in some cases to severe impairment.
EN3835-309 PFI STRIDE is a clinical study testing whether the investigational drug, EN3835, may be able to help with PFI associated pain.
To learn more or request information about enrollment, please click here.
EN3835-311 PFI is a Phase III double-blind, observational, multi-center extension study to evaluate the long-term safety, and durability (efficacy) of EN3835 in the treatment of plantar fibromatosis.
This trial is only eligible for patients who have completed the EN3835-309 PFI study.
The purpose of this study is to conduct a two-arm, prospective, randomized control trial by which participants will be randomly assigned to either receive the Dermabond wound closure adhesive or the OptiClose wound closure adhesive in participants undergoing the closure of any subcutaneous tissue following surgical site incisions.
The purpose of this research study is to evaluate the performance of the transparent gel dressing (henceforth referred to as Optiview dressing) in prevention of pressure injuries and other adverse events during both during the operation and while admitted during inpatient stay, as well as a safety assessment with respect to the use of this dressing around common operating room equipment.
The Optivew dressing is transparent and designed to be used as part of a pressure injury prevention protocol. This study product is already on the market meaning this product has been cleared for marketing by the United States Food and Drug Administration (FDA).
Nadora Healthcare has 10 private rooms available for studies that require overnight observation. Whenever there is a patient on site, we have 24/7 nursing & CNA care available. Due to our unique setup, we can allow admission for studies lasting days or even weeks at a time.
Having a multi-specialty practice, Nadora Healthcare has access to tens-of-thousands potential candidates for clinical studies. In addition, our close proximity to four suburban population centers and two densely populated major metropolitan areas provides us access to potential candidates who would participate in available studies.
Yes, Nadora Healthcare can utilize the UCHealth IRB if the CRO or sponsor does not have a requirement to utilize the IRB of their choice. Most sponsors & CRO’s that utilize Nadora Healthcare do require us to utilize the IRB of their choice, but we have one available if you do not have one.
Nadora Healthcare is independently owned by Dr. Scott Dhupar. Since our inception in 2013, it has been our mission to remain independent of investment from health systems, venture capital or private equity. We’ve maintained that independence for over a decade and will continue to function autonomously in our provision of healthcare.
Nadora Healthcare has the ability to perform surgical & non-surgical trials. Our facility has 3 operating rooms as well as 10 overnight rooms. We are able to perform device trials on surgical candidates along with healthy observation and pharmaceutical Phase I/II trials for qualified candidates.
Nadora Healthcare is a one-stop shop for patients, sponsors & CRO’s. We can conduct clinic, exams, x-ray’s, draw labs, surgery, non-surgical trials and overnight observation; along with drug storage for your organization. There is no need for a transfer and Nadora is capable of performing the higher acuity trials that other organizations may not be able to safely conduct at their location.
Nadora can respond to your protocol in roughly two weeks. We are able to provide a site visit within two weeks following submission of our protocol response and we can begin recruiting participants following approval of an agreement. Trials can typically go from inquiry to recruitment in six weeks if the CRO & sponsor are responsive.
If you’re not interested in submitting a form, you can contact Amanda Brunick, PhD directly at: Amanda.Brunick@NadoraHealthcare.com or 970-400-1551 x103.
Copyright © 2025 Nadora Healthcare
